This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
protein
product name :
Human TMEM9B (aa 126-176) Control Fragment Recombinant Protein
catalog :
RP-96579
quantity :
100 uL
price :
US 259.00
product information
Product Type :
Protein
Product Name :
Human TMEM9B (aa 126-176) Control Fragment Recombinant Protein
Catalog # :
RP-96579
Quantity :
100 uL
Price :
US 259.00
Clonality :
Recombinant
Purity :
purified
Reactivity :
Human
Applications :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Species :
Human
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
TMEM9B, also termed as Transmembrane protein 9B encodes a 198 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus. There is a dimer form of TMEM9B protein. TMEM9B mRNA is expressed in a wide range of tissues and cells. TMEM9B is a lysosomal transmembrane protein that regulates the activity of inflammatory signaling pathways.
Format :
Liquid
Applications w/Dilutions :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Aliases :
2310004K06Rik; AW539847; C11orf15; D7H11orf15; ICRFP703B1614Q5.3; ICRFP703N2430Q5.3; RGD1310775; TMEM9 domain family member B; TMEM9 domain family, member B; Tmem9b; Transmembrane protein 9B; UNQ712/PRO1375
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments